https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-01 / J. Immunother. 2008 Sep;31(7):620-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-01 / J. Immunother. 2008 Sep;31(7):620-322008-09-01 00:00:002008-09-01 00:00:00Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-01 / Best Pract Res Clin Haematol 2008 Sep;21(3):521-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-01 / Best Pract Res Clin Haematol 2008 Sep;21(3):521-412008-09-01 00:00:002019-02-15 08:32:30Dendritic cell vaccines in acute leukaemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-01 / Best Pract Res Clin Haematol 2008 Sep;21(3):421-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-01 / Best Pract Res Clin Haematol 2008 Sep;21(3):421-362008-09-01 00:00:002019-02-15 08:37:25Vaccine therapy and chronic lymphocytic leukaemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-01 / Expert Rev Vaccines 2008 Sep;7(7):937-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-01 / Expert Rev Vaccines 2008 Sep;7(7):937-492008-09-01 00:00:002019-02-15 09:19:22Melanoma vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-01 / Clin Transl Oncol 2008 Sep;10(9):543-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-01 / Clin Transl Oncol 2008 Sep;10(9):543-512008-09-01 00:00:002019-02-15 09:25:30Therapeutic vaccines for non-Hodgkin B-cell lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-25 / Pancreatology 2008;8(4-5):431-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-25 / Pancreatology 2008;8(4-5):431-612008-08-25 00:00:002019-02-15 09:23:41Biological approaches to therapy of pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-22 / Cancer Immunol. Immunother. 2009 Jan;58(1):1-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-22 / Cancer Immunol. Immunother. 2009 Jan;58(1):1-142008-08-22 00:00:002019-02-15 09:19:19Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-19 / Mol. Ther. 2008 Nov;16(11):1883-90
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-19 / Mol. Ther. 2008 Nov;16(11):1883-902008-08-19 00:00:002019-02-15 09:21:57Recombinant Newcastle disease virus as a vaccine vector for cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-12 / Hum. Immunol. 2008 Oct;69(10):614-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-12 / Hum. Immunol. 2008 Oct;69(10):614-242008-08-12 00:00:002019-02-15 08:52:02Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-01 / Curr. Opin. Mol. Ther. 2008 Aug;10(4):387-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-01 / Curr. Opin. Mol. Ther. 2008 Aug;10(4):387-922008-08-01 00:00:002019-02-15 09:21:59Oncolytic vaccinia virus: from bedside to benchtop and back
